Anti-EGFR monoclonal antibody-Tc-99 (CIMYM)

N/A

Report date: 2025/11/24 17:27:54

Base Information

Drug NameAnti-EGFR monoclonal antibody-Tc-99 (CIMYM)

Drug Alias NameDiaCIM抗EGFR单克隆抗体-Tc-99（CIMYM）DiaCIM h-R3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsDiagnostic agent (In vivo) > Radionuclide Imaging agent +[7]

Mechanisms of ActionRadionuclide imaging enhancers

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGilead Sciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGilead Sciences Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A